Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2020-12-24 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于公司2018年股票期权激励计划部分股票期权注销完成的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from 康芝药业股份有限公司 regarding the cancellation of part of the 2018 stock option incentive plan. It details the number of stock options cancelled due to employee departures and unmet performance targets, with specific figures and dates. The document is relatively short (1555 characters) and focuses on the cancellation event rather than presenting a full financial report or detailed analysis. It is not a full annual or interim report, nor is it a regulatory certification or voting result. The content fits best under a category related to capital changes, specifically stock option cancellations which affect the company's capital structure. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA).
2020-12-24 Chinese
关于注销2018年股票期权激励计划部分股票期权的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the cancellation of part of the 2018 stock option incentive plan by Kangzhi Pharmaceutical Co., Ltd. It includes specifics about the stock option plan, reasons for cancellation (employee departures and unmet performance targets), the number of options cancelled, and opinions from independent directors, the supervisory board, and legal counsel. The document is a formal announcement of a corporate action related to stock options, which is a capital structure change. It is not a full financial report, earnings release, or management discussion. It is not a proxy statement or voting result announcement. The content fits best under the category of Share Issue/Capital Change (SHA), as it deals with changes in stock option grants and cancellations affecting the company's capital structure.
2020-12-11 Chinese
独立董事关于第五届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's fifth board of directors' eleventh meeting. It includes opinions on the use of idle raised funds for cash management and the cancellation of stock options. The content focuses on board-level decisions and independent directors' assessments rather than financial results, regulatory filings, or shareholder voting outcomes. The document length is short (955 characters), and it is not a report or announcement of a report publication. It is not a certification or legal proceeding update. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2020-12-11 Chinese
广东胜伦律师事务所关于公司注销2018年股票期权激励计划部分股票期权的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of part of a 2018 stock option incentive plan by a company. It discusses legal compliance, approvals by the board and supervisory committee, and the impact on stock options due to employee departures and unmet performance targets. The document is a standalone legal opinion and not a financial report, earnings release, or regulatory filing about financial results. It is not an announcement of a report publication but a detailed legal opinion on a specific corporate action related to stock options. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is a legal compliance document that does not fit other specific categories like capital updates or management changes.
2020-12-11 Chinese
海通证券股份有限公司关于公司继续使用闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Haitong Securities regarding Kangzhi Pharmaceutical's continued use of idle raised funds for cash management. It references regulatory guidelines, the amount of funds raised, usage plans, risk control measures, and approvals by the board, independent directors, and supervisory board. The document is a formal verification or audit opinion related to the use of raised funds, not a full annual or interim financial report. It does not contain comprehensive financial statements or earnings data but focuses on compliance and risk assessment of cash management of idle raised funds. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit/verification report on a specific financial matter, not a full annual report or earnings release. The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement or report publication notice. Therefore, the best classification is AR with high confidence. FY 2020
2020-12-11 Chinese
关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 康芝药业股份有限公司 regarding the use of temporarily idle raised funds for cash management. It details the board resolution, investment product types, risk control measures, and opinions from independent directors, supervisory board, and sponsoring institutions. The document does not contain financial statements or detailed financial performance data but rather describes a corporate action related to the management of raised capital. It is a regulatory announcement about the use of funds raised from a previous issuance, specifically about cash management of idle raised funds. This fits the category of Capital/Financing Update (CAP), as it updates on the company's use of raised capital and financing activities. The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it is itself the announcement of a financing-related decision. Therefore, the appropriate classification is CAP with high confidence.
2020-12-11 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.